8-K filing — BICYCLE THERAPEUTICS PLC (BCYC)
Filed: 2026-10-29 AccNo: 0001104659-26-119858 Size: 310 KB Item 2.02: Results of Operations and Financial Condition Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Bicycle Therapeutics Reports Third Quarter 2026 Financial Results and Business Progress
Bicycle Therapeutics announced its financial results for the third quarter ended September 30, 2026, highlighting a narrowed net loss and the receipt of FDA Orphan Drug Designation for nuzefatide pevedotin.
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- fiscal.ai
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading